TW201605342A - 用於增加器官及組織保存溶液之安定性和保存期限的溶液 - Google Patents
用於增加器官及組織保存溶液之安定性和保存期限的溶液 Download PDFInfo
- Publication number
- TW201605342A TW201605342A TW103140510A TW103140510A TW201605342A TW 201605342 A TW201605342 A TW 201605342A TW 103140510 A TW103140510 A TW 103140510A TW 103140510 A TW103140510 A TW 103140510A TW 201605342 A TW201605342 A TW 201605342A
- Authority
- TW
- Taiwan
- Prior art keywords
- solution
- organ
- tissue
- sugar
- arginine
- Prior art date
Links
- 239000000243 solution Substances 0.000 title claims abstract description 217
- 210000000056 organ Anatomy 0.000 title claims abstract description 35
- 239000003761 preservation solution Substances 0.000 title claims abstract description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 56
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 48
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 28
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 22
- 239000003855 balanced salt solution Substances 0.000 claims abstract description 22
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 21
- 229930064664 L-arginine Natural products 0.000 claims abstract description 21
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 21
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 21
- 235000000346 sugar Nutrition 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 16
- 239000007864 aqueous solution Substances 0.000 claims abstract description 14
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 8
- 229960003151 mercaptamine Drugs 0.000 claims abstract 5
- 239000004471 Glycine Substances 0.000 claims abstract 4
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims abstract 4
- 210000001519 tissue Anatomy 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 34
- 108010024636 Glutathione Proteins 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 12
- 238000004321 preservation Methods 0.000 claims description 12
- 229960003180 glutathione Drugs 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 8
- 210000001367 artery Anatomy 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 210000003752 saphenous vein Anatomy 0.000 claims description 6
- 210000002216 heart Anatomy 0.000 claims description 5
- 239000000017 hydrogel Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 230000003139 buffering effect Effects 0.000 claims description 2
- -1 cysteamine glycoside Chemical class 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000001927 retinal artery Anatomy 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 3
- 239000006210 lotion Substances 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 229930182470 glycoside Natural products 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000002321 radial artery Anatomy 0.000 claims 1
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 abstract description 14
- 230000002792 vascular Effects 0.000 description 22
- 238000009472 formulation Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 239000002211 L-ascorbic acid Substances 0.000 description 7
- 235000000069 L-ascorbic acid Nutrition 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 229940105423 erythropoietin Drugs 0.000 description 4
- 238000013213 extrapolation Methods 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 208000010496 Heart Arrest Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 2
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- WXBGSMXDIABHSO-DBQHITQZSA-N 4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;methyl 4-methyl-3-[2-(propylamino)propanoylamino]thiophene-2-carboxylate;dihydrochloride Chemical compound Cl.Cl.CNC[C@H](O)C1=CC=C(O)C(O)=C1.CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC WXBGSMXDIABHSO-DBQHITQZSA-N 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 208000032750 Device leakage Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940114029 articaine / epinephrine Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 239000000162 organ preservation solution Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361963093P | 2013-11-22 | 2013-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201605342A true TW201605342A (zh) | 2016-02-16 |
Family
ID=52023642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103140510A TW201605342A (zh) | 2013-11-22 | 2014-11-21 | 用於增加器官及組織保存溶液之安定性和保存期限的溶液 |
Country Status (23)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2923441C (en) * | 2013-11-22 | 2023-03-28 | Somahlution, Llc | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution |
| EP3531832A4 (en) | 2016-10-25 | 2020-08-05 | Marquette University | SUPPORTS AND PULVERULENT FORMULATIONS FOR AVULSED TEETH AND EXPLANTED TISSUES INCLUDING FIBROBLASTS |
| US11980700B2 (en) | 2017-03-08 | 2024-05-14 | Alafair Biosciences, Inc. | Hydrogel medium for the storage and preservation of tissue |
| WO2023201038A1 (en) | 2022-04-15 | 2023-10-19 | Marizyme, Inc. | Powder formulations and use thereof in medical and/or surgical procedures |
| WO2023224887A1 (en) * | 2022-05-16 | 2023-11-23 | Marizyme, Inc. | Use of cytoprotectant formulations in cell or tissue transport and/or storage |
| EP4598347A1 (en) * | 2022-10-04 | 2025-08-13 | Marizyme, Inc. | Kits and use thereof in surgical procedures for endoscopic harvesting of vessels |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443432A (en) | 1981-10-05 | 1984-04-17 | Alcon Laboratories, Inc. | Ophthmalic irrigating solution |
| US4550022A (en) | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
| US5409904A (en) | 1984-11-13 | 1995-04-25 | Alcon Laboratories, Inc. | Hyaluronic acid compositions and methods |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US4879283A (en) | 1985-10-03 | 1989-11-07 | Wisconsin Alumni Research Foundation | Solution for the preservation of organs |
| US4837021A (en) | 1986-12-31 | 1989-06-06 | Laboratoires P.O.S. | Two part tissue irrigating solution |
| US5304724A (en) | 1988-09-09 | 1994-04-19 | Entravision, Inc. | Tissue irrigating solution |
| US4938961A (en) | 1989-04-28 | 1990-07-03 | Geoffrey Collins | Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia |
| US5257985A (en) | 1989-12-04 | 1993-11-02 | Richard Puhl | Multi-chamber intravenous bag apparatus |
| US5066578A (en) * | 1989-12-21 | 1991-11-19 | The Regents Of The University Of California | Long-term preservation of organs for transplantation |
| CA2071835A1 (en) * | 1990-11-07 | 1992-05-08 | Gerald A. Grode | Blood platelet storage medium |
| DE69126861T2 (de) * | 1990-11-07 | 1998-02-26 | Baxter Int | Lösung zur aufbewahrung roter blutzellen |
| US5498427A (en) | 1990-11-20 | 1996-03-12 | Pasteur Merieux Serums Et Vaccines | Solutions for the perfusion, preservation and reperfusion of organs |
| AU664074B2 (en) * | 1992-06-26 | 1995-11-02 | Torii Pharmaceutical Co., Ltd. | Organ preserving fluid |
| BE1007500A3 (fr) | 1992-09-18 | 1995-07-18 | Pasteur Merieux Serums Vacc | Solution de perfusion, de conservation et de reperfusion d'organes. |
| ITPD940054A1 (it) | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
| JP3623294B2 (ja) | 1995-11-28 | 2005-02-23 | 株式会社新素材総合研究所 | 電解質液が収容された医療用容器及びその製造方法 |
| US8409846B2 (en) * | 1997-09-23 | 2013-04-02 | The United States Of America As Represented By The Department Of Veteran Affairs | Compositions, methods and devices for maintaining an organ |
| US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
| US6569615B1 (en) | 2000-04-10 | 2003-05-27 | The United States Of America As Represented By The Department Of Veteran's Affairs | Composition and methods for tissue preservation |
| US7611830B2 (en) | 2000-04-10 | 2009-11-03 | The United States Of America As Represented By The Department Of Veteran's Affairs | Device to lavage a blood vessel |
| SI21704A (en) | 2004-01-14 | 2005-08-31 | Lek Farmacevtska Druzba Dd | New crystal form of perindopril, procedure of its preparation, pharmaceutical preparations containing this form and their application in treatment of hypertensia |
| US20060093765A1 (en) | 2004-10-29 | 2006-05-04 | Sealed Air Corporation (Us) | Multi-compartment pouch having a frangible seal |
| US20060160062A1 (en) | 2005-01-14 | 2006-07-20 | Young Lindon H | Perfusion and/or preservation solution for organs |
| US9078428B2 (en) | 2005-06-28 | 2015-07-14 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
| US7575856B2 (en) | 2005-10-28 | 2009-08-18 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for the evaluation and resuscitation of cadaveric hearts for transplant |
| ES2625850T3 (es) * | 2006-04-19 | 2017-07-20 | Transmedics, Inc. | Procedimientos para el cuidado de órganos ex vivo |
| EP2543249B1 (en) | 2007-02-17 | 2018-05-23 | President and Fellows of Harvard College | Compositions and method for tissue preservation |
| US20090035240A1 (en) * | 2007-07-31 | 2009-02-05 | Maes Daniel H | Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent |
| WO2009099132A1 (ja) * | 2008-02-05 | 2009-08-13 | Kyowa Hakko Bio Co., Ltd. | グルタチオンの保存安定性向上方法 |
| CA2715638A1 (en) * | 2008-02-15 | 2009-08-27 | President And Fellows Of Harvard College | Cardioplegia solution for cardiac surgery |
| US8608922B2 (en) | 2008-11-07 | 2013-12-17 | The University Of Connecticut | Biosensor for continuous monitoring of metabolites and proteins and methods of manufacture thereof |
| EP2355806A2 (en) | 2008-11-14 | 2011-08-17 | Profimed s.r.o. | Non-aqueous colloidal formulation |
| US8288084B2 (en) | 2009-07-12 | 2012-10-16 | Revive Organtech, Inc. | Composition and method for flushing and cold/cryo preserving organs, tissues, and cells |
| US10207022B2 (en) * | 2009-09-01 | 2019-02-19 | Medoderm Gmbh | Chitosan tissue dressing |
| FR2963965B1 (fr) | 2010-08-20 | 2013-02-15 | Vallourec Mannesmann Oil & Gas | Procede et dispositif de controle d'un filetage de joint tubulaire utilise dans l'industrie du petrole |
| WO2014106091A1 (en) * | 2012-12-31 | 2014-07-03 | Somahlution, Llc | Solution for preserving vascular conduits |
| CN104919066A (zh) * | 2013-01-09 | 2015-09-16 | 三菱综合材料株式会社 | 电子电气设备用铜合金、电子电气设备用铜合金薄板、电子电气设备用铜合金的制造方法、电子电气设备用导电元件及端子 |
| CA2910189A1 (en) | 2013-04-24 | 2014-10-30 | Somahlution, Llc | Organ and tissue preservation solutions having increased oxygen-content, stability and shelf life |
| US20160088832A1 (en) * | 2013-04-29 | 2016-03-31 | Somahlution, Llc | Formulations containing poly (0-2 hydroxyethyl) starch for increasing the oxygen-content, stability and shelf life of an organ and tissue preservation solution |
| CA2923441C (en) * | 2013-11-22 | 2023-03-28 | Somahlution, Llc | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution |
-
2014
- 2014-11-18 CA CA2923441A patent/CA2923441C/en active Active
- 2014-11-18 SG SG10201709595WA patent/SG10201709595WA/en unknown
- 2014-11-18 WO PCT/US2014/066054 patent/WO2015077199A1/en not_active Ceased
- 2014-11-18 CN CN201480061943.3A patent/CN105916374B/zh not_active Expired - Fee Related
- 2014-11-18 DK DK14812052.0T patent/DK3027016T3/da active
- 2014-11-18 KR KR1020167015581A patent/KR102428676B1/ko active Active
- 2014-11-18 ES ES14812052T patent/ES2744637T3/es active Active
- 2014-11-18 US US14/906,582 patent/US11291201B2/en active Active
- 2014-11-18 JP JP2016525916A patent/JP2016537333A/ja active Pending
- 2014-11-18 MY MYPI2016701801A patent/MY181282A/en unknown
- 2014-11-18 EP EP14812052.0A patent/EP3027016B1/en active Active
- 2014-11-18 EA EA201691066A patent/EA201691066A1/ru unknown
- 2014-11-18 MX MX2016006651A patent/MX378411B/es unknown
- 2014-11-18 PE PE2016000488A patent/PE20160861A1/es not_active Application Discontinuation
- 2014-11-18 AU AU2014353199A patent/AU2014353199B2/en active Active
- 2014-11-18 KR KR1020227026130A patent/KR102570322B1/ko active Active
- 2014-11-18 BR BR112016006512-3A patent/BR112016006512B1/pt not_active IP Right Cessation
- 2014-11-21 AR ARP140104385A patent/AR098508A1/es active IP Right Grant
- 2014-11-21 TW TW103140510A patent/TW201605342A/zh unknown
-
2016
- 2016-03-30 IL IL244834A patent/IL244834B/en active IP Right Grant
- 2016-04-05 ZA ZA2016/02253A patent/ZA201602253B/en unknown
- 2016-04-22 CR CR20160188A patent/CR20160188A/es unknown
- 2016-04-27 CL CL2016001003A patent/CL2016001003A1/es unknown
- 2016-05-17 PH PH12016500909A patent/PH12016500909B1/en unknown
-
2022
- 2022-03-02 US US17/684,495 patent/US20220232822A1/en active Pending
- 2022-10-04 ZA ZA2022/10899A patent/ZA202210899B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220232822A1 (en) | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution | |
| ES2724238T3 (es) | Formulaciones para la preservación de órganos y tejidos con mayor estabilidad y vida útil | |
| TW201521577A (zh) | 用於增加器官及組織保存溶液之氧含量、安定性及保存壽命的含聚(0-2-羥乙基)澱粉調配物 | |
| OA17766A (en) | Solutons for increasing the stability and shelf life of an organ tissue preservation solution | |
| HK1220081B (en) | Solutions for increasing the stability and shelf life of an organ tissue preservation solution | |
| TWI524843B (zh) | 保存血管導管之溶液 | |
| EP2988594A1 (en) | Organ and tissue preservation solutions having increased oxygen-content, stability and shelf life | |
| TWI540961B (zh) | 具有增加安定性及儲存壽命的器官及組織保存調配物 | |
| OA17544A (en) | Solution for preserving vascular conduits. | |
| AU2013370276A1 (en) | Solution for preserving vascular conduits |